Bihar Mukhyamantri Haemophilia Yojana

Bihar Mukhyamantri Haemophilia Yojana: Free Emicizumab Treatment for Haemophilia Patients

Haemophilia treatment is a lifelong expense, and the newest medicines are far out of reach for most families. Bihar’s Mukhyamantri Haemophilia Yojana will give haemophilia patients free access to Emicizumab, an advanced non-factor medicine, funded by the state.

Not open for applications yet. The Bihar Cabinet approved the scheme on 30 September 2026, but detailed guidelines, the application process and a helpline have not been released. Everything below reflects the announcement, and details may change once the official guidelines are issued.

What is the scheme?

The Cabinet approved the scheme on 30 September 2026, chaired by Chief Minister Samrat Choudhary. It is funded through the Chief Minister’s Medical Assistance Fund, and the Health Department, Government of Bihar, is expected to be the nodal agency.

Haemophilia is a rare genetic condition in which blood doesn’t clot normally. It can cause prolonged or spontaneous bleeding, easy bruising and joint pain, and patients often need costly medication for life.

Emicizumab works differently from standard clotting-factor treatments and is given less often, which can make regular care easier. It is also very expensive: a single vial costs ₹39,723, and a patient weighing around 30 kg needs 78 vials.

Scheme at a glance

The 255 figure may rise once the scheme is rolled out and more patients register. The ₹26.33 crore is an administrative sanction for the scheme’s first year, not an amount paid to individual patients.

What will patients get?

• Treatment support through Emicizumab (non-factor medicine)
• Better, more consistent access to haemophilia treatment through government support

Not yet specified: the medicine quantity, dosage, hospital-wise distribution and other treatment details.

Who will be eligible?

Detailed patient-level criteria have not been released. Based on the announcement and the Medical Assistance Fund’s usual conditions, the likely requirements are:

• The applicant is a haemophilia patient.
• The applicant is a domiciled resident of Bihar.
• Annual family income does not exceed ₹4 lakh, as prescribed for treatment assistance under the Fund.
• The patient meets the medical and other conditions the government prescribes.

Not yet specified: age limit, haemophilia type and detailed medical criteria.

Documents

No official list has been published. Based on the nature of the scheme, you may need:

• Aadhaar card or other valid identity proof
• Residence certificate from the competent authority
• Income certificate. Under the Medical Assistance Fund, it should be issued by the District Magistrate, Sub-Divisional Magistrate or Circle Officer.
• Medical prescription from a Bihar Government hospital or a CGHS-recognised hospital
• Any other document the Health Department or the treatment centre prescribes

Wait for the official guidelines before submitting anything.

How to apply

There is no application process yet. The government hasn’t said how patients will register, whether it will be online or offline, or how verification and medicine distribution will work.

For now, you can check:

• The Bihar Health Department official website
• The State Health Society, Bihar Thalassaemia & Haemophilia Registry Portal

Related support in Bihar

The scheme adds to existing haemophilia care in the state, including:

• The Haemophilia Hospital in Patna
• Day-care centres for haemophilia and thalassaemia patients, set up earlier in 2026 across six major medical colleges

Bihar also runs similar disease-specific schemes: the Bihar Shatabdi Kust Kalyan Yojana for leprosy patients and the Bihar Shatabdi Aids Pirit Kalyan Yojana for AIDS-affected patients.

Need help?

No dedicated helpline has been released. Contact the Bihar Health Department or your treating hospital for updates.

Frequently asked questions

What is the main benefit?
Free access to Emicizumab for eligible haemophilia patients in Bihar.

How much has the government approved?
A first-year administrative sanction of ₹26.33 crore.

Is the ₹26.33 crore given directly to patients?
No. It is the scheme’s first-year funding, used to provide the medicine.

How many patients will benefit?
255 have been identified so far, and the number may grow.

How can patients apply?
This has not been announced. Await the official guidelines.